Clinical Trials | November 27, 2025
Otsuka files FDA application for first-in-class ADHD drug
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
IND application for EB-003 expected in early 2026
The survey revealed that the proportion of individuals experiencing constant thoughts about food throughout the day declined by 46 percent after starting Wegovy
Products manufactured at the new Vaughan facility will support research in areas including cancer, infectious disease, mental health, and environmental safety
Subscribe To Our Newsletter & Stay Updated
